← Directory
Policy controversy
Big PharmaAtlas
Health & Medicine · Pharmaceutical industry
Competing accounts of whether drug companies steer the FDA and the medicine people get, versus imperfect but still independent public oversight, without offering treatment guidance.
Open the caseDocumented7
- Documented · Congressional committees have held public hearings that examine federal health-agency performance, funding, and related public-health outcomes.
- Documented · EMA publicly describes industry fees as part of its funding mix.
- Documented · FDA publishes user-fee program descriptions and related performance goals.
- Documented · Federal user-fee statutes for prescription drugs are repeatedly cited in arguments about structural dependence of regulators on industry payments.
- Documented · GAO periodically reviews FDA programs and capacity.
- Documented · Legislative reauthorization cycles for prescription drug user-fee programs are a recurring venue for oversight debate about regulator incentives and capacity.
- Documented · PDUFA was first enacted in 1992 and has been reauthorized in multi-year cycles.
Official3
- Official · Independent congressional audit bodies periodically review U.S. drug-regulator programs and organizational capacity.
- Official · Major drug regulators publicly describe industry user fees as part of their funding arrangements and related performance-goal frameworks.
- Official · The U.S. Food and Drug Administration has publicly discussed operational challenges such as managing drug shortages.
Contested2
- Contested · Competing public accounts disagree on whether major drug regulators are systematically tilted by industry funding and career incentives or remain imperfect but independent public overseers.
- Contested · European and U.S. medicines regulators both figure in comparative claims about industry fee influence versus retained public independence.